/

KRBPQ

Kiromic BioPharma, Inc.Closed

0.0001000.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.005000

Prev close

0.000100

Day range

0.0050000.005000

52-week range

0.0000100.005000

Volume

10.00K40.49×

Mkt cap

265

P/E ttm

—

Fwd P/E

—

EPS ttm

-3.17

Div yield

0.00%

Earnings

—

From 52w high

−98.00%

Price Chart

Yahoo Finance · delayed

KRBPQOct 12, 2026O 0.0001H 0.0001L 0.0001C 0.00010.0000 (0.00%)

SMA 500.0001
SMA 2000.0001

1Y change −98.00% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KRBPQ Kiromic BioPharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: 0.00%
1 month: 0.00%
3 months: 0.00%
6 months: 0.00%
Year to date: 0.00%
1 year: −98.00%

Valuation & ownership

Market cap: 265
Enterprise value: 13.43M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: -0.62
EPS (ttm): -3.17
EPS (forward): —
Beta (5y monthly): 0.26
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 2.65M
Float: 1.19M
Short % of float: 6.82%
Short ratio (days): 1.45
Held by insiders: 2.29%
Held by institutions: 0.00%
Avg volume (3m): 247
50-day average: 0.000100
200-day average: 0.000095
52-week change: −98.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 65.8
vs 50-day SMA: 0.00%
vs 200-day SMA: +5.21%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 0.00%
Realised vol (20d, ann.): 0.0%
From 52-week high: −98.00%
From 52-week low: +900.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): +314.70%
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Kiromic BioPharma, Inc.

Yahoo Finance profile

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Sector: Healthcare
Industry: Biotechnology
Employees: 44
Headquarters: Houston, TX, United States
Website: kiromic.com
Officers: Mr. Pietro Bersani CPA, J.D. Chief Executive Officer

SEAS

Seasonality · KRBPQ

2020–2026 · monthly returns

Strongest month Feb +28.10%Weakest month Jul −32.48%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.0	-90.0	900.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			−0.0%
2025	-0.0	66.7	-92.0	-49.6	0.0	-40.8	-83.2	-33.3	25.0	-94.0	0.0	-66.7	−100.0%
2024	48.3	101.9	9.4	-7.5	21.4	-31.6	-13.5	10.3	-33.0	-17.9	-20.9	-1.1	+3.4%
2023	15.7	-11.2	-30.6	5.0	-21.8	-14.2	-9.6	-25.6	-84.2	-13.8	-4.0	262.6	−84.0%
2022	-28.1	-37.7	24.6	-29.3	-42.6	22.7	-22.8	12.8	-21.6	2.8	-13.6	-29.9	−88.2%
2021	5.5	20.8	-12.9	-10.2	-3.9	-40.8	-33.3	7.5	-11.0	-27.4	19.7	-42.7	−81.9%
2020											-12.5	-0.4	−12.8%

KRBPQ

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KRBPQ

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kiromic BioPharma, Inc.

Seasonality · KRBPQ

Insider Activity · KRBPQ

Congress Trades · KRBPQ

Investors Holding KRBPQ

Investors Holding KRBPQ

Congress Trades · KRBPQ

Insider Activity · KRBPQ

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Kiromic BioPharma, Inc.

Earnings & Dividends

News

Seasonality · KRBPQ